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OBJECTIVE
This review is aimed at gathering and analyzing information 
from research conducted from different countries in Asian 
countries and summarizes the overall epidemiology, risk 
factors, treatment options and challenges of CVT seen in Asia. 
METHODS
An extensive literature search was conducted first using the 
terms CVT in Asia and then looking at individual Asian 
countries. The countries included in the search comprised of 
Japan, Thailand, Singapore, Indonesia, Malaysia, Korea, 
China, India, Pakistan, Israel, Saudi Arabia and Kuwait. Only 
registries or case series’ with greater than 20 cases were 
reviewed. The search query cerebral venous thrombosis within 
Asia yielded 108 results, after reviewing them for relevance 
and substance, 16 articles from all over Asia were included in 
this review.
Incidence
There is a dearth of population based incidence surveys related 
to CVT in most Asian countries. A prospective population based 
survey conducted in the Isfahan region of Iran, between 
2001-04, found the annual incidence of CVT to be 12.1 per 
million people (4).
Age
CVT has always been considered a disease of young people. 
A study, which included 109 CVT patients from Dubai and 
Karachi between the years 1991 and 2007, found the 
median age of the patients to be 35 (mean, 35.8); the 
females were 5 years younger than the males; mean age of 
women, 33.2; mean age of men, 38.7 years. (5) The mean 
age of CVT sufferers was found to be 35.5 years; [36.3 in 
men and 35.3 in women] in an Iranian study mentioned 
above, which recorded a total of 1122 patients. (4) An Indian 
study conducted between 2002 and 2010 in Hyderabad, 
which included 428 people. found that the mean age of 
presentation was 31.3 years (6), similar results were 
obtained by Pai et al who found that the mean age of their 
population of 612 people was 31.9 years  A large multi 
centred study which included 204 women who suffered 
from CVT from India, Pakistan, Sri Lanka, Syria, Thailand, 
Singapore, Turkey and Iran found that the mean age of 
presentation was 29.0 years (7). The mean age reported by 
Misra et al in their RCT comprising of 66 patients from India 
was 34.5 years (8). Poungvarin et al reported a mean age of 
36.6 years in their study population (9). When comparing 
this Asian data with the findings of the ISCVT, we can see 
that the mean age of onset is significantly lower in our 
population as compared to the European population studied, 
the main age of presentation of the 628 patients enrolled in 
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the study being 39.1 and median being 37.0 years (3)
Gender
CVT has traditionally been thought to predominate amongst 
women. A study that included patients from Pakistan and 
the Middle East found the division of their patients to be 
53.0% women and 47.0% men (5). Janghorbani et al found 
that out of 122 patients with CVST in Isfahan, 26 (21.3%) 
were men and 96 (78.7%) were women. (4) However, an 
Indian study reported that of its 428 CVT patients, 53.7% 
were men and 46.3% were women (6). Misra et al studied 
66 patients with CVT and reported that 62.1% of their study 
population were women, and 37.9% were men, further re 
demonstrating a female predominance towards the condi-
tion (8). Poungvarin et al reviewed 194 patients with CVT in 
Thailand between 1993 and 2005 and found that 127 
(65.5%) were women (9). When comparing this information 
with the results of the ISCVT, where 74.5% of CVT patients 
were female and 25.5% male (3), we can see that our data 
is generally consistent with international trends when 
looking at gender distribution.
CVT in Children
CVT in children is a result of complex multifactorial elements 
which result in a prothrombotic state, usually arising from 
the interaction of  acute and chronic pathologies (10). 
Janghorbhani et all reported a total of 3 cases per a popula-
tion of 227, 941 people in the 15-19 age group (4). An 
Indian study conducted between 2001 and 2010 reported 
that 39 of its 624 CVT patients were children (11). Ozbek et 
al looked at a 122 pediatric patients of venous thrombosis 
in Ankara, Turkey and found that 28 (22.9%) had CVT. 54% 
of all thrombotic patients had an inherited form of hyperco-
aguability, the most common being MTHFR 677C-t muta-
tion with factor V leiden coming in second. (12)
Risk Factors
There are several risk factors for CVT, including both modifia-
ble and non modifiable. The most significant non modifiable 
risk factor would be female gender as noted by literature 
from Pakistan, Iran and the Middle East (5)(7)(13). This female 
predisposition has largely been attributed to the risk factors 
of puerpurium and oral contraceptive pill use (5)(7)(6). Another 
significant risk factor would be hypercoagulability due to 
inherited or acquired thrombophilia, deficiencies of protein 
C, S or antithrombin III,hyperhomocysteinemia, or presence 
of anti-phospholipid or anti cardiolipin antibodies as demon-
strated by several studies undertaken in Pakistan, India, the 
Middle East and Japan (5)(6)(7)(11)(14)(15). Infections have also 
been demonstrated as a significant risk factor towards the 
development of CVT (5)(7)(15). Other risk factors demonstrated 
include anemia and alcoholism (6)(7)(14). Patil et al reported 
dehydration to be a risk factor precipitating CVT in their 
review of 50 patients in a tertiary care setting in India.(16)
Daif et al identified Behcet’s disease as a significant risk 
factor for the development of CVT in their series of 40 
patients in the Saudi population, with 10 of the 40 CVT 
patients (25%) suffering from Behcets disease, they also 
found that 3 of their 40 patients (7.5%) suffered from 
intracranial tumors. (15). Al Hashel et al, in their retrospective 
review of 110 patients in Kuwait, found that 10 of the CVT 
patients also suffered from Behcet’s disease (9.1%), 
redomnstrating this particular risk factor specific to the Arab 
population. (17). When comparing our findings to the results 
of the ISCVT, we found that several risk factors overlapped. 
34.1% of cases were identified to have thrombophilias, 
congenital or acquired. 5.9% had antiphospholipid antibod-
ies present. 4.5% had hyperhomocysteinemia. Other risk 
factors identified that correlated with our data include 
anemia (9.2%), infection (12.3%), pregnancy (6.3%), 
puerperium (13.8%), use of oral contraceptive pills (54.3%) 
and malignancy (7.4%). A significant risk factors identified 
in the ISCVT that we did not see in our literature were 
mechanical precipitants including trauma, LPs, or a jugular 
catheter (4.5%) (3)
Treatment
The mainstay of therapy in acute and sub acute CVT is 
anticoagulation. There are several rationales for anticoagu-
lation therapy in CVT: To prevent thrombus growth, to 
facilitate recanalization, and to prevent DVT or PE (18). A 
study in Iran that included 122 patients reported that all 
were anticoagulated; Thirty-two patients (26.2%) were 
anticoagulated with heparin only, 75 (61.5%) patients 
treated with heparin and anticonvulsive drugs, 8 (6.6%) 
patients treated with low molecular weight heparin and 7 
(5.7%) patients treated with heparin plus antibiotics (4). 
Similarly, in a study conducted in Pakistan and the Middle 
East; 73 of 109 (67%) received acute anticoagulation, 10 
(9%) received low-dose subcutaneous heparin for deep 
venous thrombosis prophylaxis and 10 (9%) received 
antiplatelet agents. None of the patients underwent throm-
bolysis. Antibiotics were administered to 28 (26%) of the 
patients. 4 of these underwent neurosurgical intervention 
(frontal lobectomy in 2, hematoma evacuation in 1, and 
ventriculoperitoneal shunt in 1). Thirteen patients received 
steroids, 7 received mannitol, and 3 received acetazola-
mide (5).  In an Indian study, similar treatment methods were 
reported; 396 (92.5%) patients received unfractionated 
heparin for 7 days overlapping with oral anticoagulants for 3 
days which was continued for a minimum period of 6 
months. LMWH was given in 41 (9.5%) of patients, who 
had massive hemorrhagic infarcts with midline shift. Six 
patients (1.4%) not showing a satisfactory response to 
unfractionated heparin were administered intrasinus uroki-
nase under catheter guidance via the trans femoral route. 
Decompression craniotomy was done in 16 (3.7%) 
patients(6). In another study conducted amongst women 
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Table 1. studies conducted in Asian countries
#
 
Country Author No ofPatients 
Male/
Female
Risk Factors Treatment Outcome
India Narayan
et al   
428 
M=53.7%  
F= 46.3% 
 
Anemia(18.4%)
 
Hyperhomocysteineimia
(18.2%)  
Alcoholism (15.6%)
Protein S deficiency
(12.3%) 
OCP use (11.4%)
 
 
 
UFH (92.5%)
 
LMWH (9.5%)  
Intrasinus
urokinase
(1.4%)   
 
Death (7.7%) 
Functionally
dependent
(25.7%)   
Functionally
independent
mRS = 2
(10.9%)   
Complete
recovery
(52.8%)  
Pakistan
and UAE  
Khealani
et al  
109 M = 47% 
F = 53% 
Infection (18%)  
 
 Postpartum state (17%),  
Hyperhomocystinemia(9%) 
 
Genetic thrombophilia (5%) 
 
 Oral contraceptive pill
use (3%)   
Acute
anticoagulation
(67%)   
Low dose
subcutaneous
agents (9%)  
 
Anti platelet
agents (9%) 
 
Antibiotics  
Death (9%)  
Functionally
dependent
(7%)  
Functionally
independent
(56%)  
 
3
2
1
 Saudi 
Arabia 
Daif et al 40 M = 50%
F = 50%
 
Behçet’s disease (25%)  
Antiphospholipid
antibodies (10%) 
 
 
Protein S deficiency
(7.5%) 
 
 
Intracranial tumors(7.5%)   
SLE (7.5%) 
Repeated LPs
(27.5%)  
Steroids/acetaz
olamide (20%) 
Heparin (10%) 
 
Death (10%) 
Functionally
dependent/disa
bled (17.5%) 
 
Complete
recovery (72%) 
 
4 Kuwait Al Hashel
et al   
110 M = 
37.3% 
F =
62.7%  
Behcet’s disease (9%) UFH (50%)  
 LMWH (27%)  
Warfarin (18%) 
5 Japan Shindo
et al 
22 Congenital thrombophilia Poor prognosis
(mRS 3-5)  
Decompression
craniotomy
(3.7%)  
from 8 different Asian countries including India, Pakistan, 
Sri Lanka, Iran, Thailand, Turkey and Syria found that 
anticoagulation was the most frequent treatment, used in 
122 patients (61%), and followed by antiplatelet therapy in 
75 patients (37%). Three patients (1.5%) underwent 
surgical decompression. No patients received thrombolytic 
therapy (7). Daif et al reported treating 11 (27.5%) patients 
by repeated lumbar puncture. Steroids and/or acetazolamide 
were used in 8 (20%) patients. 4 (10%) patients were 
treated with heparin (15). Misra et al compared the safety 
and efficacy of LMWH to unfractionated heparin in a 
randomized control trial with 32 people receiving 
unfractionated heparin and 34 receiving LMWH. Baseline 
characteristics were similar between the two groups, 6 
patients died, all of them belonging to the unfractionated 
heparin group. At 3 months’ follow up 30 patients in the 
LMWH group had recovered completely as opposed to 20 in 
the unfractionated group, one patient had to have therapy 
withdrawn from the unfractionated group due to heparin 
induced thrombosis, these results indicate the superiority of 
LMWH over unfractionated heparin in terms of outcomes 
(16).When comparing this to the ISCVT, we find marked 
similarities, in their population 520 or (83.3%) of patients 
were anticoagulated with intravenous heparin (401 cases 
[64%]) or subcutaneous low-molecular-weight heparin 
(LMWH) (218 patients [34.9%]). A few patients received 
only subcutaneous LMWH in prophylactic dosage 9 patients 
(1.4%) or antiplatelet drugs 37 patients (5.9%). Thirteen 
patients (2.1%) were treated with local endovascular throm-
bolysis. Additional treatments included antiepileptic drugs 
277 patients (44.4%), osmotherapy 82 (13.2%), steroids 
150 (24.1%), acetazolamide 61 (9.8%), and diuretics 34 
(5.5%). Shunts were performed in 10 patients (1.6%), 9 
(1.4%) had decompressive craniotomy or hematoma 
evacuation (3).
Outcome
Outcomes for CVT, like other forms of stroke vary. Khealani 
et al found that of their 109 patients, fifty were either dead 
(n = 7) or disabled with a modified Rankin score of greater 
than 2 (n = 43) (5). Khan et al looked at 110 women with 
pregnancy related strokes from Pakistan, India, Iran, Sri 
Lanka and Turkey found that of patients with CVT, 14.3% at 
a modified Ranikin score of greater than 3 at a 30 day 
follow up (19). Narayan et al found that of their 428 
patients, 33 (7.7%) died during their hospital stay, 90 days’ 
follow up was available for 416 patients, of these 226 
(52.8%) were normal with a mRS of 0 to 1, 47 (10.9%) had 
become functionally independent with a mRS of 2, and 110 
(25.7%) were functionally dependent with a mRS of 3 to 5 
(6). Poungvarin et al reported that 51 of their 194 patients 
(26.3%) had a mRS of 3 to 6 with poor outcomes, with an 
overall mortality rate of 8.4%. They were able to identify 
certain factors that determined the nature of the outcome. 
Poor outcomes were associated with malignancy, low GCS 
and presence of hemorrhagic infarction. The involvement of 
the lateral sinus was associated with good outcomes (9). Pai 
et al reported a mortality of 12.9% in their population of 
612 adults and children, 18.3% were reported as being 
wheelchair bound or functionally dependant, 35.5% had 
varying degrees of disability and 23.3% had recovered 
completely at a one year follow up with 5 cases being lost to 
follow up (11).When comparing this to the findings of the 
ISCVT, several similarities can be appreciated. Of the 624 
adult patients enrolled in the study, 356 (57.8%) had no 
symptoms at the end of follow up (median 16 months), 
137 (22%) had minor residual symptoms with a mRS of 1 
and 47 (7.5%) had mild impairment with a mRS of 2. 18 
(2.9%) were moderately impaired with a mRS of 3, 14 
(2.2%) were severely handicapped with a mRS of 4 or 5 
and 52 (8.3%) had died.
CHALLENGES AND FUTURE DIRECTION
One of the greatest challenges posed during this review was 
the paucity of representative data from the Asian region, 
with only one country having reliable epidemiological data of 
CVT by virtue of setting up a registry. There is also dearth of 
literature available when focusing specifically on CVT in 
children even though it has shown to affect them as well 
and is traditionally referred to as an illness of children and 
young people. CVT is a significant cause of stroke in the 
young Asian population so it would be prudent to establish 
better systems of recording its frequency, course and 
outcomes. 
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